(Q35964754)

11 August 2017

1 reference

title

Dengue vaccine: priorities and progress (English)

1 reference

11 August 2017

0 references

María G Guzmán

1

1 reference

11 August 2017

Mayra Muné

series ordinal

2

1 reference

11 August 2017

Gustavo Kourí

series ordinal

3

1 reference

11 August 2017

language of work or name

1 reference

1 December 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

1 reference

11 August 2017

2

1 reference

11 August 2017

6

1 reference

11 August 2017

895-911

1 reference

The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

West Nile encephalitis: an emerging disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Flavivirus genome organization, expression, and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Early clinical and laboratory indicators of acute dengue illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

The future of dengue vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Development of new vaccines against dengue fever and Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Dengue and dengue haemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Risk perception and strategies for mass communication on dengue in the Americas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Viruses Associated with Epidemic Hemorrhagic Fevers of the Philippines and Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Pathogenesis of dengue: challenges to molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Immunopathogenesis of dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Immunopathogenesis of Dengue hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Why dengue haemorrhagic fever in Cuba? 2. An integral analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Effect of age on outcome of secondary dengue 2 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Molecular evolution and epidemiology of dengue-3 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Epidemiologic studies on Dengue in Santiago de Cuba, 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Traditional and novel approaches to flavivirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

From the World Health Organization. Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Study of bivalent dengue vaccine in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Live attenuated tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Structures of immature flavivirus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Immune response to synthetic peptides of dengue prM protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

An analysis of the antibody response against West Nile virus E protein purified by SDS-PAGE indicates that this protein does not contain sequential epitopes for efficient induction of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Activation of dengue protease autocleavage at the NS2B–NS3 junction by recombinant NS3 and GST–NS2B fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Towards a new generation of flavivirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Dengue 2 Virus Envelope Protein Expressed by a Recombinant Vaccinia Virus Fails to Protect Monkeys against Dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Vaccines for the prevention of neglected diseases--dengue fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

The causes and consequences of genetic variation in dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

The origin, emergence and evolutionary genetics of dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Dengue Type 3 Virus in Plasma Is a Population of Closely Related Genomes: Quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Early Immune Activation in Acute Dengue Illness Is Related to Development of Plasma Leakage and Disease Severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.6.895

Research on dengue during World War II

21 January 2018

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4269/AJTMH.1952.1.30

Identifiers

DOI

10.1586/14789072.2.6.895

1 reference

11 August 2017

1 reference